

## DRUG QUANTITY MANAGEMENT POLICY – PER RX

**POLICY:** Wakefulness-Promoting Agents – Sunosi Drug Quantity Management Policy – Per Rx

- Sunosi™ (solriamfetol tablets – Axome)

**REVIEW DATE:** 08/31/2022

---

### OVERVIEW

Sunosi, a dopamine and norepinephrine reuptake inhibitor, is indicated **to improve wakefulness in adults with excessive daytime sleepiness** associated with the following conditions:<sup>1</sup>

- Narcolepsy.
- Obstructive sleep apnea (OSA).

### Dosing

The initial recommended dose of Sunosi in adults with narcolepsy is 75 mg once daily (QD).<sup>1</sup> The dose range for Sunosi for the treatment of narcolepsy is 75 mg to 150 mg QD. Based on efficacy and tolerability, the dosage of Sunosi may be doubled at intervals of at least 3 days. The maximum recommended dose is 150 mg QD.

The initial recommended dose of Sunosi in adults with OSA is 37.5 mg QD.<sup>1</sup> The dosage range for Sunosi for the treatment of OSA is 37.5 mg to 150 mg QD. Based on efficacy and tolerability, the dosage of Sunosi may be doubled at intervals of at least 3 days. The maximum recommended dosage is 150 mg QD. Doses > 150 mg QD do not confer increased effectiveness sufficient to outweigh dose-related adverse reactions.

For patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30 to 59 mL/min/1.73m<sup>2</sup>), the maximum recommended daily dose is 75 mg.<sup>1</sup> For patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m<sup>2</sup>) the maximum recommended daily dose is 37.5 mg. Sunosi is not recommended for use in patients with end stage renal disease (eGFR < 15 mL/min/1.73m<sup>2</sup>).

### Availability

Sunosi is available as 75 mg and 150 mg tablets in bottles of 30 tablets.<sup>1</sup> The 75 mg tablets are scored and can be split.

### POLICY STATEMENT

This Drug Quantity Management program has been developed to promote dose consolidation, prevent stockpiling/waste and to address potential order entry error of Sunosi. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

**Automation:** None.

**Drug Quantity Limits**

<b>Product</b>	<b>Strength and Form</b>	<b>Retail Maximum Quantity per Rx</b>	<b>Home Delivery Maximum Quantity per Rx</b>
Sunosi® (solriamfetol tablets)	75 mg tablets	30 tablets	90 tablets
	150 mg tablets	30 tablets	90 tablets

**CRITERIA**Sunosi 75 mg tablets

1. If the patient is titrating their dose from 75 mg daily to 150 mg daily, approve a one-time override of 60 tablets at retail or 120 tablets at home delivery.

Note: This home delivery quantity is sufficient for 60 days of 75 mg once daily dosing and up to 30 days of 150 mg once daily dosing. The 150 mg tablets should be used for continued dosing at 150 mg once daily.

Sunosi 150 mg tablets

No overrides recommended.

**REFERENCES**

1. Sunosi® tablets [prescribing information]. New York, NY: Axome; June 2022.